Moleculin Biotech (MBRX) Research & Development (2016 - 2026)
Moleculin Biotech (MBRX) posted quarterly Research & Development of $5.1 million for Q4 2025, up 14.86% year-over-year from $4.5 million in Q4 2024, and up 36.89% quarter-over-quarter from $3.7 million in Q3 2025.
Moleculin Biotech (MBRX) Research & Development (2016 - 2026) Analysis & Trends
Moleculin Biotech's Research & Development history runs 10 years deep, the most recent figure standing at $5.1 million for Q4 2025.
- In Q4 2025, Research & Development rose 14.86% year-over-year to $5.1 million; the TTM figure through Dec 2025 stood at $15.9 million (down 10.37% YoY), while the FY2025 annual figure was $15.9 million, down 10.37% from the prior year.
- Research & Development for Q4 2025 stood at $5.1 million, up from $3.7 million in the prior quarter.
- The five-year high for Research & Development was $6.6 million in Q4 2023, with the low at $3.0 million in Q2 2021.
- The 5-year median for Research & Development is $4.1 million (2021), against an average of $4.3 million.
- The sharpest annual moves came in 2021 and 2023: Research & Development jumped 78.0% in 2021, then plunged 45.01% in 2023.
- Moleculin Biotech's Research & Development stood at $3.2 million in 2021, then surged by 31.42% to $4.2 million in 2022, then soared by 58.74% to $6.6 million in 2023, then plunged by 32.83% to $4.5 million in 2024, then gained by 14.86% to $5.1 million in 2025.
- Business Quant data shows MBRX's Research & Development at $5.1 million in Q4 2025, $3.7 million in Q3 2025, and $3.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Moleculin Biotech | 3.35 Mn | 3.35 Mn | - | 5.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.45 Mn |
| Dec 31, 2025 | 5.12 Mn |
| Sep 30, 2025 | 3.74 Mn |
| Jun 30, 2025 | 3.60 Mn |
| Mar 31, 2025 | 3.44 Mn |
| Dec 31, 2024 | 4.46 Mn |
| Sep 30, 2024 | 4.93 Mn |
| Jun 30, 2024 | 4.09 Mn |
| Mar 31, 2024 | 4.25 Mn |
| Dec 31, 2023 | 6.63 Mn |
| Sep 30, 2023 | 3.28 Mn |
| Jun 30, 2023 | 3.89 Mn |
| Mar 31, 2023 | 5.69 Mn |
| Dec 31, 2022 | 4.18 Mn |
| Sep 30, 2022 | 5.97 Mn |
| Jun 30, 2022 | 4.20 Mn |
| Mar 31, 2022 | 4.62 Mn |
| Dec 31, 2021 | 3.18 Mn |
| Sep 30, 2021 | 4.10 Mn |
| Jun 30, 2021 | 3.04 Mn |